Home| Netegrity (acquired by IBM) |
$2.18 to $73.20 | 3487% |
| Inhibitex (acquired by |
$2.35 to $24.08 | 925% |
| Cellstar | $1.44 to $13.50 | 837% |
| Iomega | $3.25 to $13.90 | 328% |
| Nanophase | $3.75 to $16.75 | 347% |
| Immunomedics | $1.44 to $29.12 | 1922% |
| Total Renal Care | $3.12 to $26.95 | 741% |
| Voxware | $ .90 to $10.31 | 1046% |
| Corvas | $3.00 to $23.25 | 675% |
| Cytogen | $2.12 to $17.50 | 725% |
| Verilink | $3.00 to $14.62 | 387% |
| GeneLabs | $2.31 to $10.72 | 364% |
WHAT DOES BIDEN'S ELECTION MEAN FOR THE MARKETS?
Right now, not much. All eyes are still on a COVID vaccine and when it will be ready for mass distribution. The market's long-term health could very well be in the hands of Georgia residents come January 5. Those two Senate seats not only have national implications, but worldwide consequences.